HDAC9 and sarcoma: Following the breakthrough of the approval of ImatinibTM/Gleevec® for the treatment of gastrointestinal stromal tumours, other specific targets have been identified for sarcomas such as PDGFRα and β, c-Met, PI3K-AKT, HDAC, MDM2 and IGF1R, and inhibitors targeting these pathways have been developed and evaluated in preclinical and clinical trials.25,26